// App-Quantinova.ai

3860 : The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma

Researchers

Presenter

  • Cynthia M. Simbulan-Rosenthal

Principal Investigators

  • Sivanesan Dakshanamurthy

  • Anirudh Gaur

  • You-Shin Chen

  • Rena Shimizu

  • Maryam Abdus Sumad

  • Hengbo Zhou

  • John Zapas

  • Valerie Calvert

  • Emaneul F. Petricoin

  • Michael B. Atkins

  • Stephen W. Byers

  • Dean S. Rosenthal

Medical Centers

  • George Washington University School of Medicine, Washington, DC

  • University of Colorado Hospital, Aurora, CO

  • Surgical Specialists Monocacy Health Partners, Frederick, MD

  • George Mason University, Institute for Advanced Biomedical Research, Manassas, VA.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • B-Raf proto-oncogene, serine/threonine kinase

  • Extracellular signal-regulated kinase

Drug/Treatment

  • Mebendazole

  • Dabrafenib Mesylate

  • Trametinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved